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Background: In addition to its general and periodontal health effects smoking causes tooth staining. Smoking
cessation support interventions with an added stain removal or tooth whitening effect may increase motivation to
quit smoking. Oral health professionals are well placed to provide smoking cessation advice and support to
patients. The objective of the present study was to evaluate the effect of NicoretteW Freshmint Gum used in a
smoking cessation programme administered in a dental setting, on extrinsic stain and tooth shade among smokers.
Methods: An evaluator-blinded, randomized, 12-week parallel-group controlled trial was conducted among 200
daily smokers motivated to quit smoking. Participants were randomised to use either the NicoretteW Freshmint
Gum or NicoretteW Microtab (tablet). Tooth staining and shade were rated using the modified Lobene Stain Index
and the VitaW Shade Guide at baseline, weeks 2, 6 and 12. To maintain consistency with other whitening studies,
the primary end-point was the mean change in stain index between baseline and week 6. Secondary variables
included changes in stain measurements and tooth shade at the other time points the number of gums or tablets
used per day and throughout the trial period; and the number of cigarettes smoked per day. Treatments were
compared using analysis of covariance (ANCOVA), using treatment and nicotine dependence as factors and the
corresponding baseline measurement as a covariate. Each comparison (modified intention-to-treat) was tested at
the 0.05 level, two-sided. Within-treatment changes from baseline were compared using a paired t-test.
Results: At week 6, the gum-group experienced a reduction in mean stain scores whilst the tablet-group
experienced an increase with mean changes of -0.14 and +0.12 respectively, (p = 0.005, ANCOVA). The change in
mean tooth shade scores was statistically significantly greater in the gum-group than in the tablet group at 2
(p = 0.015), 6 (p = 0.011) and 12 weeks (p = 0.003) with greater lightening in the gum-group at each examination
period.
Conclusion: These results support the efficacy of the tested nicotine replacement gum in stain reduction and
shade lightening. These findings may help dentists to motivate those wishing to quit smoking using a nicotine
replacement gum.
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Development of nicotine replacement products with
oral benefits could provide smokers with additional
motivation to quit smoking and give dental profes-
sionals an additional reason to introduce the topic of
smoking cessation with their patients. Availability of
a smoking cessation product with stain removal or
tooth whitening activity would provide an opportun-
ity for dentists to illustrate some early measurable
benefits of smoking cessation, reinforce smokers’
commitment to quit and support them on the path
to a stable state of not smoking.
Nicotine replacement therapy (NRT) is the most
widely-used effective treatment for tobacco depend-
ence [1]. One of the most common cosmetic effects
of cigarette smoking is the deposition of heavy stain
on teeth. Results from in vitro tests suggest that
NicoretteW Freshmint Gum (nicotine polacrilex gum)
used for smoking cessation may have stain reducing
(whitening) effects on smokers’ teeth [2]).
The act of gum chewing is associated with several
beneficial effects including increased saliva output
and mechanical removal of debris and dental stains
[3]. NicoretteW Freshmint Gum also contains
NaHCO3 (sodium bicarbonate), Na2CO3 (sodium
carbonate) and CaCO3 (calcium carbonate) - three
ingredients also found in commercially available
tooth-whitening products; and xylitol, a chelating
agent non-fermentable sugar which stimulates saliv-
ary flow and interferes with bacterial adhesion to
oral tissues thus helping to reduce the risk of caries
[4,5]. The combination of high-pH buffers (sodium
bicarbonate, sodium carbonate) and an abrasive
agent (calcium carbonate) in conjunction with saliv-
ary stimulation resulting from the gum flavour (xyli-
tol) and chewing action are likely to have a positive
impact on stained teeth while the gum is being used
for smoking cessation.
This hypothesis is supported by data from a recent
in vitro trial which demonstrated that the nicotine
replacement gum (2 mg and 4 mg strengths) was
comparable with, or better than, some leading teeth-
whitening brands of confectionary gums [2].
According to the literature, other studies per-
formed with commercial whitening gums demon-
strated a reduction in the stain index from week 2
onwards [6-13]. Subjects in these studies may have
been partially supervised and, most importantly, the
trial designs did not specifically address smokers.
The hypothesis tested in this study was that a
nicotine replacement gum removes more stain and
whitens teeth more during a 6-week smoking cessa-
tion programme than a nicotine replacement sub-
lingual tablet.Methods
The objectives of this study were to assess extrinsic
stain reduction from baseline while quitting smoking
using either NicoretteW Freshmint Gum (nicotine
polacrilex) or NicoretteW Microtab (nicotine beta-
cyclodextrin); a neutral sublingual tablet with no
whitening properties compared to the gum. The pri-
mary efficacy parameter was the mean change in the
modified extrinsic tooth stain score (all sites) between
baseline and 6 weeks as this was consistent with the
duration of other whitening studies. A secondary out-
come measures was the change in tooth shade, mea-
sured by the Vita Shade Guide, between baseline and
Weeks 2, 6 and 12.
The duration of the current trial in smokers was 12
weeks, with observations at weeks 2, 6 and 12.
Thus, the study was an evaluator-blinded, rando-
mized, 12-week parallel group controlled trial which
compared the stain reduction efficacy of a nicotine re-
placement gum against the reference product a nico-
tine replacement sub-lingual tablet in healthy smokers
motivated to quit smoking and with visible staining of
teeth. It was conducted in compliance with the ethical
principles originating in or derived from the Declar-
ation of Helsinki and with all International Confer-
ence on Harmonization (ICH) Good Clinical Practice
(GCP) Guidelines [14]. The Irish Medicines Board and
the Clinical Research Ethics Committee of The Cork
Teaching Hospitals, approved the study, trial partici-
pants provided informed consent.
Stain was measured using the MacPherson Modifi-
cation of the Lobene Stain Index [9] which scores
eight sites per tooth, four facial and four lingual or
palatal. The stain score per tooth site was determined
by multiplying the score for stain intensity (scores 0-3)
by that for stain area (scores 0-3). The test teeth were
the eight incisors; if one of the eight incisors was not
present or scorable, a canine was substituted. The
stain score per subject was determined by averaging
scores across tooth sites for that subject.
The intrinsic tooth shade was visually graded using a
traditional VitaW Lumin Shade guide as a reference
standard (VITA Zahnfabrik, H.Rauter GmbH & Co.
KG, D-79713 Bad Säckingen, Germany). The shade
assessments were made under standardized lighting
conditions: assessments were all conducted in the
same windowless room using color-corrected lighting
in the range of 5000 degrees Kelvin, with the subject
seated in a special upright examining chair with the
arch tooth position parallel to the floor. A blue bib
was placed over the subject's clothing, and all lipstick
was removed before scoring. Color shade values for
the upper right central incisor and upper left lateral
incisor were determined by selecting one VitaW Lumin
Whelton et al. BMC Oral Health 2012, 12:13 Page 3 of 7
http://www.biomedcentral.com/1472-6831/12/13Shade sample that most closely matched each tooth.
For analysis, each of the 16 shade tabs was assigned a
number from 1 (dark) to 16 (light) according to the

















An increase in difference from baseline after treat-
ment suggests an improvement in tooth shade. Subject
scores were computed for each visit by averaging indi-
vidual scores across teeth. Change from baseline was
computed for each subject using these averages.
Inclusion criteria were a minimum of 20 natural
teeth present with at least 10 of the 12 anterior teeth
present and scorable, and a total extrinsic facial tooth
stain score ≥ 28 according to Lobene stain index.
Teeth that were grossly carious, fully crowned, or ex-
tensively restored on the facial or lingual surfaces were
not included in the tooth count.
The trial was carried out at the Oral Health Services
Research Centre in University College Cork over a 5
month period between July and November. The flow
of subjects into and through the trial is illustrated in
the CONSORT flow chart [16] in Figure 1. Of the 546
adults assessed for eligibility, 200 smokers were ran-
domized at baseline to receive either the nicotine re-
placement gum or the nicotine replacement tablet to
help them quit smoking. Reasons for non-enrollment
are outlined in Figure 1. Subjects were classified
according to the Fagerström Test for Nicotine De-
pendence (FTND) [17]. The randomization schedule
was produced by the sponsor using an SAS Based
Randomization Generator. The randomization was
stratified according to 8 combinations of nicotine de-
pendence level (defined as Low = Fagerström Total ≤ 5
and High = Fagerström Total ≥ 6) and baseline facial
stain level (defined as sum of the facial scores equal to
28-49, 50-74, 75-99, or ≥ 100). Participants were allo-
cated to groups at the study site by the local clinicaltrial coordinator, according to the randomisation
schedule. The examiner was blind to the group alloca-
tion and participants were asked not to break the
examiner blinding. High-nicotine dependent smokers
(FTND ≥ 6,) received nicotine 4 mg gum or were
instructed to use a 4 mg dosage of the tablet (2
tablets); low-nicotine dependent smokers (FTND ≤ 5)
received nicotine 2 mg gum or were instructed to use
a 2 mg dosage of the tablet (one tablet). The trial com-
prised of five visits: Baseline (entry visit), week one,
week 2, week 6 and week 12 (study end). A trained and
calibrated examiner rated tooth stain and shade at
baseline and weeks 2, 6 and 12. Intra-examiner reli-
ability was checked by repeat examination of 11 sub-
jects with dental staining prior to study examinations.
At all visits after baseline, smoking status and use of
study treatment (gum or tablets) was checked. All sub-
jects were instructed to use the chewing-gum or sub-
lingual tablet for 12 weeks and to quit smoking the
day after enrolment. Subjects were advised to use the
trial medication (gum or tablet) frequently in accord-
ance with product labelling to minimize symptoms of
tobacco deprivation. The maximum recommended
dosage per day was 15 x 4 mg pieces of gum or 40 x 2
mg tablets for the high-nicotine dependent group, and
15 x 2 mg pieces of gum or 20 x 2 mg tablets for the
low-nicotine dependent group. Smoking status was
assessed by self-reported abstinence and biochemically
verified by measuring the level of CO in exhaled air,
using a Bedfont monitor [18].
Oral care was standardized throughout the trial. At
baseline, subjects were given a soft-bristled tooth-
brush and regular fluoride toothpaste and instructed
to brush their teeth no more than twice a day. Use of
any other oral hygiene or tooth-whitening product
was prohibited during the trial. There were no dietary
or drink restrictions. All observed or volunteered Ad-
verse Events, the severity (mild, moderate, or severe)
of each event, and the investigator’s opinion of the re-
lationship to the trial medication were recorded.
Statistical analysis
Using results from two previous oral care studies
using the same index, a reasonable estimate of the
standard deviation for the mean stain score was 1.1.
Given this standard deviation, the current trial needed
50 completers per treatment group to have 90% power
to detect a 0.73 unit difference. Assuming a 50% drop-
out rate, a sample size of 100 subjects per group at
baseline (total of 200 subjects enrolled) was planned.
Analyses of primary and secondary variables were
based on data from modified intent-to-treat (ITT)
subjects, defined as all randomized subjects who had
used the clinical trial test products and who had
Assessed for eligibility
(n= 546  )
Excluded (n= 346)
Not meeting inclusion criteria (n= 293)
Refused to participate (n=17)
Other reasons (n= 36)
Analyzed (n=52)
Excluded from analysis (n= 0)
Lost to follow-up (n= 23)
Discontinued intervention (n= 27)
Allocated to Freshmint Gum intervention 
(n= 102)
Lost to follow-up (n=18)
Discontinued intervention (n=30)
Allocated to Microtab intervention
(n=98)
Analyzed (n= 50)






Figure 1 Flow of subjects through tooth stain removal study. The flow of subjects through the study is shown according to the CONSORT
Statement [16].
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from smoking was self-reported, and validated by an
expired CO level of less than 10 ppm.
The primary outcome variable was the mean change
in modified extrinsic tooth stain index (all sites) from
baseline to week 6; this study duration was consistent
with other tooth whitening studies in the literature
[3,10-13] and was also consistent with the FDA´s def-
inition of the primary time-point for smoking cessa-
tion efficacy (6 weeks with complete abstinence for
the last four weeks).The full study ran for 12 weeks
according to the design of traditional smoking cessa-
tion studies. The secondary outcome variables were:
the mean change from baseline in modified extrinsic
tooth stain score (based on all scored sites) at weeks 2
and 12 and in surface stain scores at different sites,
stain area and intensity at weeks 2, 6 and 12; the
change from baseline in tooth shade measured using
the VitaW Shade Guide at weeks 2, 6, and 12; the num-
ber of gums or tablets used per day and throughout
the trial period; and the number of cigarettes smoked
per day.
Demographic and baseline characteristics were
compared across treatment groups using either ana-
lysis of variance (ANOVA) or a chi-square test. If theexpected number of subjects within a specific cat-
egory was sufficiently small, Fisher’s exact test was
used instead of the chi-square test. Treatments were
compared using analysis of covariance (ANCOVA),
using treatment and nicotine dependence as factors
and the corresponding baseline measurement as a
covariate. Each comparison was tested at the 0.05
level, two-sided.
Results
Repeat examination of 11 subjects with dental stain-
ing resulted in ϰ statistics of 0.88 and 0.84 in intensity
and area for intra-examiner reliability. A value of 0.99
was achieved for vita shade. Two hundred subjects
(mean age 35.7 years) were enrolled in the study
(Table 1). The flow of participants throughout the
study is illustrated according to the CONSORT state-
ment in Figure 1 [16]. At baseline, subjects smoked a
mean of 19.2 ± 8.0 cigarettes/day, their mean FTND
score was 4.5 ± 2.44; 57% of subjects had made 2-5
quit attempts. At baseline, the total mean stain index
was 4.2 ± 1.53 and the mean VitaW Shade score was
10.4 ± 3.24. One hundred and two subjects received
nicotine gum, and 98 received nicotine tablets. A total
of 102 subjects completed the 12-week trial.
Table 1 Summary of Demographic and Baseline Variables
(All Randomized Subjects)
Variables Gum Tablet Total
(N= 102) (N=98) (N=200)
Age (years)
Mean 35.2 36.3 35.7
Sex
Male 50 (49.0%) 54 (55.1%) 104 (52.0%)
Female 52 (51.0%) 44 (44.9%) 96 (48.0%)
Cigarettes/Day
Mean 18.7 19.8 19.2
Median 20.0 20.0 20.0
Min,Max (5,40) (5,60) (5,60)
Fagerström Test for Nicotine Dependence (FTND) Score Total
Mean 4.5 4.4 4.5
Median 4.0 4.5 4.0
Min,Max (0,9) (0,10) (0,9)
Total Mean Stain Index
Mean 4.1 4.3 4.2
S.D. 1.5 1.5 1.5
Median 4.3 4.3 4.3
VitaW Shade Score
Mean 10.5 10.2 10.4
S.D. 3.3 3.1 3.2
Median 11.0 10.0 11.0
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The intent-to-treat abstinence rates at week 6 were
41.2% (42/102) in the gum group and 36.7% (36/98) in
the tablet group; at week 12, 35.3% (36/102) in the
gum group and 37.8% (37/98) in the tablet group. The
mean self-reported numbers of cigarettes smoked per
day in the gum group and tablet group at weeks one,
2, 6 and 12 was less than or equal to 1.05 cigarette per
day. The average use of gum or tablets was 8-9 pieces
of 2 or 4mg gum and 8-16 tablets per day according
to nicotine dependence category.
Efficacy results
The primary outcome variable was the mean change
in stain index scores between baseline and week 6.
The level of stain was lower at week 6 than at baseline
in the gum group (test) with a mean reduction of -0.14
and higher than at baseline in the tablet group (con-
trol) with a mean increase of 0.12 (Table 2). This dif-
ference in mean change in stain index scores between
baseline and week 6 was statistically significant in
favour of gum (p 0.005, ANCOVA).At week 2 the mean change in stain index scores
from baseline indicates a stain reduction in the gum
group (-0.02) and an increase in the tablet group
(0.05), however the difference in these mean changes
were not significant (p = 0.147). At week 12, mean
change in stain index scores in the gum and tablet
group were -0.7 and -0.5 respectively, indicating stain
reduction from baseline in both groups with no sig-
nificant difference between the groups (p = 0.74).
Concerning site and area specific changes, statisti-
cally significant improvements in lingual stain index,
body region stain index, and total stain area were
noted with the gum group compared with the tablet
group. At week 6, treatment with gum did not improve
facial stain index or total stain intensity; however, the
increases in facial stain index and total stain intensity
in the gum group were smaller than the corresponding
increases in the tablet group.
The change from baseline in the tooth shade at weeks
2, 6 and 12 were measured as secondary outcome vari-
ables. There was a greater degree of shade lightening in
the gum group compared with the tablet group,
p = 0.015, 0.011, 0.003 at 2, 6 and 12 weeks respectively
(Table 3). Whilst the change in scores from baseline
indicated a progressive lightening at the three time
points in the gum group, the change in shade scores in
the tablet group showed a darkening at weeks 2 and 6
and the mean change from baseline at week 12 was zero.
The most common treatment-related adverse events
were gastrointestinal disorders (reported by 21.6% of
gum and 36.7% of tablet users), headache (22.5% gum
vs. 17.3% tablet), sore mouth, hiccups, and cough.
Most treatment-related adverse events were mild and
transient. No serious treatment-related adverse events
occurred during the study. One subject in the gum
group discontinued treatment because of mild nausea
and headache that were probably or possibly related to
treatment.
Discussion
The improvements in staining that occurred in the
gum group were primarily due to reduced staining on
the lingual surfaces. The reductions in the stain index
(all surfaces) were primarily due to reductions in stain
area, rather than reductions in intensity. These find-
ings suggest that the gum had most impact on removal
of newer stain, and less impact on removal of older
stain. Although the stain index reduction from base-
line in the gum group is modest, it is worth noting
that, in contrast, the tablet group showed an increase
in stain from baseline. This increase in stain in the
tablet group is possibly a result of the dietary habits of
this traditionally heavy tea-drinking population. Thus
the reduction in stain in the gum group suggests an
Table 3 VitaW Shade Tooth Assessment (Intent-To-Treat
Subjects)
Week 2 Week 6 Week 12
Gum Tablet Gum Tablet Gum Tablet
N 78 70 60 59 52 50
Baseline
Mean 10.8 10.0 10.8 10.1 10.9 10.1
S.D. 3.2 3.2 3.15 3.23 3.15 3.18
Median 11.8 10.3 11.8 10.5 11.8 10.5
Min,Max (2.0,15.0) (3.0,15.0) (2.5,15.0) (3.0,15.0) (2.5,15.0) (3.0,15.0)
Post
Mean 10.9 10.0 11.1 10.1 11.4 10.1
S.D. 3.1 3.2 3.1 3.2 3.2 3.2
Median 12.0 10.1 12.0 10.5 12.0 10.8
Min,Max (2.0,15.0) (3.0,15.0) (2.0,15.0) (3.0,15.0) (2.0,15.0) (2.0,15.0)
Change
Mean 0.16 -0.03 0.28 -0.06 0.50 0.00
S.D. 0.70 0.17 0.94 0.55 1.16 0.64





0.047 0.159 0.023 0.411 0.003 >0.999
LsMean 0.17 -0.04 0.25 -0.11 0.44 -0.12
s.e. 0.06 0.06 0.10 0.10 0.13 0.14
Comparison vs. Microtab
p-value 0.015a 0.011a 0.003a
Difference0.21 0.36 0.56
s.e. 0.09 0.14 0.18
95% C.I. [0.04,0.38] [0.09,0.64] [0.19,0.92]
aP-values are based on ANCOVA model with terms for Treatment.
Note: Based on Munsell color ranking from 1= darkest to 16 = lightest shade.
Table 2 Tooth –wise Mean Stain Index Total
(Intent-To-Treat Subjects)
Week 2 Week 6 Week 12
Gum Tablet Gum Tablet Gum Tablet
N 78 70 60 59 52 50
Baseline
Mean 4.1 4.3 4.2 4.3 4.2 4.4
S.D. 1.6 1.6 1.6 1.6 1.7 1.6
Median 4.3 4.2 4.3 4.3 4.4 4.4
Min,Max (1.30,7.52) (0.73,7.77) (1.30,7.52) (0.73,7.77) (1.30,7.52) (1.31,7.77)
Post
Mean 4.1 4.3 4.0 4.4 4.1 4.4
S.D. 1.6 1.6 1.7 1.7 1.7 1.6
Median 4.1 4.3 4.2 4.6 4.4 4.1
Min,Max (1.22,7.27) (0.75,7.73) (1.02,7.45) (0.69,7.45) (1.19,7.11) (1.17,7.63)
Change
Mean -0.02 0.05 -0.14 0.12 -0.07 -0.05
S.D. 0.34 0.33 0.46 0.50 0.46 0.60





0.536 0.191 0.018 0.079 0.251 0.588
LsMean -0.03 0.05 -0.13 0.12 -0.09 -0.05
s.e. 0.04 0.04 0.06 0.06 0.08 0.078
Comparison vs. Microtab
p-value 0.147a 0.005a 0.74a
Difference-0.08 -0.25 -0.04
s.e. 0.06 0.09 0.11
95% C.I. [-0.19,0.03] [-0.43,-0.08] [-0.25,0.17]
aP-values are based on ANCOVA model with terms for Treatment.
Note: Lower number indicates less stain.
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by the gum in addition to the statistically significant
modest stain removal found in this study.
The stain reduction in the gum group was not statisti-
cally significant at 12 weeks although the shade score
was statistically significantly lighter (p = 0.003). The
results of this study suggest that stain removal and tooth
whitening are added benefits of using the nicotine re-
placement gum. These findings may offer an added in-
centive for smokers to quit smoking. The dental
practitioner is well placed to encourage smokers to quit
[19] and with the advantage of tooth whitening for their
patients, may find it easier to broach the subject of
smoking cessation. The results of this study are relevant
to other health care workers who recommend nicotine
replacement gum as the improvement in tooth stain and
shade were not dependent on the dental setting becausethe study design did not incorporate any professional
cleaning of the teeth.Conclusion
The results of this study confirm that chewing the tested
nicotine replacement gum as recommended in a ‘real
world’ active smoking cessation program produces a sta-
tistically significant change in the parameter of whiten-
ing as measured by change from baseline versus the
negative control (Microtab) following 6 weeks in a
smoking cessation programme. The VitaW Shade Guide
(the secondary outcome measure) supported the trend
of stain improvement. These results support the efficacy
of the tested nicotine replacement gum in stain reduc-
tion, in arresting the progression of tooth stain and in
shade lightening.
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